2015
DOI: 10.1016/j.vetpar.2014.12.009
|View full text |Cite
|
Sign up to set email alerts
|

A vaccine formulation combining rhoptry proteins NcROP40 and NcROP2 improves pup survival in a pregnant mouse model of neosporosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
20
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 25 publications
(20 citation statements)
references
References 64 publications
0
20
0
Order By: Relevance
“…However, worries about safety, resumed virulence, and increased numbers of carrier animals restricted their use in eld applications. In recent years, with the identi cation of new antigens, several dense granule (GRA) and rhoptry (ROP) proteins in N. caninum have been identi ed that could be used in diagnostics or as vaccine candidates [15,16,17]. Considering their safety and ease of preparation, vaccine development based on recombinant antigens offers many advantages over live-attenuated and inactivated vaccines.…”
Section: Discussionmentioning
confidence: 99%
“…However, worries about safety, resumed virulence, and increased numbers of carrier animals restricted their use in eld applications. In recent years, with the identi cation of new antigens, several dense granule (GRA) and rhoptry (ROP) proteins in N. caninum have been identi ed that could be used in diagnostics or as vaccine candidates [15,16,17]. Considering their safety and ease of preparation, vaccine development based on recombinant antigens offers many advantages over live-attenuated and inactivated vaccines.…”
Section: Discussionmentioning
confidence: 99%
“…rNcNTPase and rNcGRA7 proteins were obtained as previously described [ 30 ]. Briefly, proteins were cloned in the pET45b(+) expression system (Novagen), expressed in E. coli BL21(DE3) pLysS competent cells (Agilent Technologies) as a (His)6-tagged fusion proteins, and purified using HisTrapHP columns coupled to the ÄKTAprime Plus system (GE Healthcare).…”
Section: Methodsmentioning
confidence: 99%
“…Quil A was also used in an experimental vaccine against N. caninum , partially protecting mice against cerebral infection when s.c. co-administered with a N. caninum lysate (65). In a more recent research, Pastor-Fernández et al (55) showed that i.p. immunization with different recombinant antigens from N. caninum (rNcROP4, rNcROP2, rNcGRA7, and rNcNTPasa) as monovalent or pair-wise combinations (rNcROP40 + rNcROP2 and rNcGRA7 + rNcNTPase) + Quil A, increased specific immune responses, decreased parasite burden in brain and partially protected against vertical transmission in a pregnant mouse model of congenital neosporosis.…”
Section: Adjuvants: the Black Box Of Immunology Being Openedmentioning
confidence: 97%